Go back to the enewsletter Scenic Luxury Cruises

first_imgGo back to the enewsletterScenic Luxury Cruises & Tours has just confirmed the first sailing date for Scenic Eclipse has been pushed back until 15 August 2019. Cumulatively, the delays have put the ship nearly 12 months behind its original launch date of 31 August 2018.“We are deeply sorry for the inconvenience these delays to the launch of Scenic Eclipse have caused our guests. As a company we have done everything possible to complete the ship within the time limits that were set previously, but a series of events that are outside our control have put us in a position where we must delay,” stated a company spokesperson.Ongoing financial challenges faced by Uljanik Shipyard, where Scenic Eclipse is being built, have caused a range of ongoing impacts, the Australian company said.“Shipyard workers have not been paid full salaries since August 2018, which has led to strikes and manpower shortages as well as several other shipyard disruptions, resulting in months of lost production. To keep the build moving as quickly as possible in these challenging circumstances Scenic has expanded the team within the shipyard by employing Cruise Ship specialists from Finland, Italy, the UK and Norway.“The expanded Scenic team took over the lead role in completing the ship, with in excess of 115 directly employed specialists in cooperation with the shipyard’s remaining management team and more than 500 subcontractors,” Scenic added.There is, however, a silver lining. Scenic has said a “very positive development” for the Scenic Eclipse build – and the Uljanik Group – was a partnership between the Croatian DIV Group and Italian shipyard Fincantieri. This consortium was confirmed as the new owner of Uljanik on 7 February 2019.Scenic said it is now “confident that these new owners will bring stability and focus to current and future ship builds.”Accordingly, the Scenic Group has signed a letter of intent with the new consortium that will lead the shipyard to set up a new Discovery Yacht division within the restructured Uljanik group. This new joint venture will be fully focused on completing Scenic Eclipse and on expediting the build of the second Scenic Eclipse, as well as progressing development of the next generations of Scenic’s Discovery Yachts.Guests impacted by the latest delay are being offered a full refund for the cost of their Scenic Eclipse cruise and consideration of any other reasonable associated costs incurred with their travel plans. In addition, Scenic will provide all guests who rebook a Scenic Eclipse voyage a future cruise credit to the value of 25% of the cost of their rebooked cruise.Scenic has established a dedicated phone number for guests and has begun reaching out to all guests and travel agents to provide details on the process of refunding and offering an opportunity to apply the 25% discount to other voyages.Lead image: Scenic Eclipse as of January 2019 at the Uljanik Shipyard.Go back to the enewsletterlast_img read more

Fighting sepsis with cancer drugs

first_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Click to view the privacy policy. Required fields are indicated by an asterisk (*) Inflammation may help you fight off invading microbes, but it can also kill you, leading to insufficient blood flow and even organ failure. A new study shows that some cancer drugs may be able to quell the excessive inflammation that occurs in conditions such as sepsis, which is responsible for more than 250,000 deaths in the United States each year.Inflammation is a normal immune response to a pathogen threat, involving the production of various chemical signals and the activation of immune cells like neutrophils. Yet its effects can be deadly on a massive scale. Researchers suspect, for example, that the 1918–1919 flu pandemic, which killed as many as 40 million, was so lethal because it sent inflammation spiraling out of control. Over-the-top inflammation is also a hallmark of sepsis, in which the body overreacts to an infection. There are few options for treating people with sepsis, which can cause their organs to stop working and can be fatal within hours.Molecular biologist Ivan Marazzi of the Ichan School of Medicine at Mount Sinai in New York City and colleagues set out to explore how various cells control the activity of genes that promote inflammation. They exposed human and mouse cells to one of two viruses, activating the cells’ immune genes. The team then tested several different compounds that affect how DNA is packaged in cells—the idea being that the compounds might alter the activity of these genes. One of the compounds that curbed gene activity, camptothecin, is a cancer treatment. Of the tested compounds, Marazzi says. “it probably would have been the last” he would have expected to work. Camptothecin kills cancer cells by blocking the enzyme topoisomerase I, which removes kinks from DNA so that it can be duplicated or read to produce proteins. The team’s findings suggest that topoisomerase I also helps orchestrate the immune system’s response to pathogen attacks.To determine whether blocking topoisomerase I could thwart out-of-control inflammation, the researchers injected mice with a bacterial poison that triggers septic shock, a severe form of sepsis, and then dosed some of the mice with camptothecin. All of the untreated mice died within about 40 hours, whereas 90% of the mice that received camptothecin survived, the researchers report online today in Science. The drug also allowed 70% of mice to live through an infection with the bacterium Staphylococcus aureus, which can cause sepsis in humans. Only 11% of untreated animals survived the infection. People who have the flu are particularly susceptible to bacterial infections that can lead to sepsis. Marazzi and colleagues found that captothecin protected mice suffering from these dual infections, saving 94% of them, whereas all of the untreated mice perished.The study “provides an extremely intriguing and promising strategy,” says immunopathologist Peter Ward of the University of Michigan, Ann Arbor, who wasn’t connected to the research. But he wants to see further animal studies to confirm that blocking topoisomerase is effective against other types of bacteria that more commonly cause sepsis in people.The findings are encouraging, says molecular biologist Murat Kaynar of the University of Pittsburgh School of Medicine in Pennsylvania. However, he cautions that many potential sepsis treatments that were promising in animal studies haven’t panned out in human studies. “We’ve had a lot of failed trials,” he says.Although topoisomerase I is not a specialized immune system enzyme, the researchers found that it has a big impact on some genes that control inflammation, says molecular immunologist Stephen Smale of the University of California, Los Angeles. Thus “the study by Marazzi and colleagues shows the value of broadening the search for inhibitors of inflammatory responses,” he says.Camptothecin is one of several topoisomerase I–inhibiting cancer drugs that have received approval from the Food and Drug Administration. Marazzi says that he and his colleagues are working with a pharmaceutical company to organize a clinical trial to test whether blocking topoisomerase I is beneficial during sepsis. Although such inhibitors can trigger problems such as bleeding and infections, patients with sepsis would only need a small number of doses, so these side effects would be less likely, Marazzi predicts. “We have a potential treatment for a deadly disease that kills millions of people worldwide.”center_img Email Sign up for our daily newsletter Get more great content like this delivered right to you! Countrylast_img read more